Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
about
Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatmentRecent advances in Cys-loop receptor structure and functionDecoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models.Congenital myasthenic syndromes in 2012.What have we learned from the congenital myasthenic syndromesPoly(ethylene glycol) as a scaffold for high-affinity open-channel blockers of the mouse nicotinic acetylcholine receptor.Serum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromesCurrent status of the congenital myasthenic syndromes.Zebrafish model for congenital myasthenic syndrome reveals mechanisms causal to developmental recovery.The therapy of congenital myasthenic syndromes.COLQ-mutant Congenital Myasthenic Syndrome with Microcephaly: A Unique Case with Literature ReviewAcetylcholine receptor gating in a zebrafish model for slow-channel syndrome.Selective cleavage of AChR cRNAs harbouring mutations underlying the slow channel myasthenic syndrome by hammerhead ribozymes.A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome.New insight into the stereoselective interactions of quinine and quinidine, with bovine serum albumin.Makaluvamine G from the Marine Sponge Zyzzia fuliginosa Inhibits Muscle nAChR by Binding at the Orthosteric and Allosteric Sites.
P2860
Q28082722-E1E304B7-3BC8-448B-8076-160F42FBF4E6Q28303306-2F73EEF3-D302-4071-81DA-395A9EFD1D6DQ34087906-D9EA7EFE-AE67-4ACD-9D0F-6B354D9CA014Q34407051-6B1539C7-1DD2-4131-9350-55B650D97536Q34632327-6CF1BB80-2E89-4C73-A69D-A5EBC3BAB430Q35409841-1CA1238A-6A73-4775-A53C-B4C1D396BB8EQ35623707-1895AC9D-4F5B-4FB3-BD6A-A9AEF8214FA7Q35718489-F387BB4D-9A04-4B5A-A90B-72082A25B590Q36378523-6FD1F5C2-CA5D-4B75-97A8-3B58B4E8F110Q36774720-720F2E09-979F-4A12-9EA1-5F3B2AC87BBDQ39458487-684C9FDD-C6F0-4F61-A331-033C175DA1C6Q42226282-C8357F7F-A942-47A1-B140-FE53B7D7E322Q42544646-0F0C45AF-B39C-454C-9FAD-D398AB2283CDQ42612222-2007224D-AD44-4E25-9FFC-8C3CE36C1205Q45570638-D8EE60C0-8D48-4F44-94B8-5CDBCB26CEDBQ52621347-78209CE9-5286-4770-ABB3-ACE7A89B763D
P2860
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@ast
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@en
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@en-gb
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@nl
type
label
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@ast
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@en
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@en-gb
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@nl
prefLabel
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@ast
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@en
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@en-gb
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@nl
P921
P356
P1433
P1476
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
@en
P2093
P356
10.1002/ANA.410430411
P407
P577
1998-04-01T00:00:00Z